Great West Life Assurance Co. Can reduced its position in Perrigo Company (NYSE:PRGO) by 5.7% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 101,694 shares of the company’s stock after selling 6,090 shares during the period. Great West Life Assurance Co. Can’s holdings in Perrigo were worth $7,675,000 as of its most recent filing with the SEC.
A number of other institutional investors have also recently modified their holdings of the company. Johnson Financial Group Inc. raised its position in shares of Perrigo by 15.6% in the first quarter. Johnson Financial Group Inc. now owns 1,775 shares of the company’s stock worth $118,000 after buying an additional 240 shares in the last quarter. Global X Management Co. LLC raised its position in shares of Perrigo by 56.4% in the first quarter. Global X Management Co. LLC now owns 2,370 shares of the company’s stock worth $157,000 after buying an additional 855 shares in the last quarter. Teza Capital Management LLC purchased a new position in shares of Perrigo during the first quarter worth approximately $205,000. State of Alaska Department of Revenue purchased a new position in shares of Perrigo during the first quarter worth approximately $214,000. Finally, Bank of Nova Scotia raised its position in shares of Perrigo by 2.5% in the first quarter. Bank of Nova Scotia now owns 3,219 shares of the company’s stock worth $214,000 after buying an additional 80 shares in the last quarter. Hedge funds and other institutional investors own 76.38% of the company’s stock.
Shares of Perrigo Company (NYSE PRGO) opened at 78.49 on Friday. The company’s 50-day moving average is $73.59 and its 200 day moving average is $73.05. The firm’s market cap is $11.25 billion. Perrigo Company has a 1-year low of $63.68 and a 1-year high of $99.14.
Perrigo (NYSE:PRGO) last released its quarterly earnings data on Thursday, August 10th. The company reported $1.22 EPS for the quarter, topping analysts’ consensus estimates of $0.94 by $0.28. The company had revenue of $1.24 billion during the quarter, compared to the consensus estimate of $1.18 billion. Perrigo had a negative net margin of 51.04% and a positive return on equity of 11.37%. The firm’s revenue for the quarter was down 7.7% compared to the same quarter last year. During the same period last year, the firm earned $1.93 EPS. On average, equities research analysts expect that Perrigo Company will post $4.32 EPS for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 12th. Stockholders of record on Friday, August 25th will be issued a dividend of $0.16 per share. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.82%. The ex-dividend date of this dividend is Wednesday, August 23rd. Perrigo’s payout ratio is -3.51%.
COPYRIGHT VIOLATION WARNING: This news story was originally reported by Transcript Daily and is the sole property of of Transcript Daily. If you are reading this news story on another site, it was copied illegally and reposted in violation of United States and international trademark and copyright laws. The correct version of this news story can be viewed at https://transcriptdaily.com/2017/08/13/perrigo-company-prgo-stake-reduced-by-great-west-life-assurance-co-can.html.
A number of equities analysts have commented on the stock. Royal Bank Of Canada reiterated a “hold” rating and issued a $68.00 price objective on shares of Perrigo in a report on Wednesday, May 3rd. Stifel Nicolaus restated a “hold” rating on shares of Perrigo in a research note on Friday. Canaccord Genuity set a $80.00 target price on shares of Perrigo and gave the company a “buy” rating in a research note on Wednesday, May 31st. Deutsche Bank AG cut their target price on shares of Perrigo from $87.00 to $86.00 and set a “buy” rating on the stock in a research note on Wednesday, April 19th. Finally, Cantor Fitzgerald set a $85.00 target price on shares of Perrigo and gave the company a “buy” rating in a research note on Monday, July 24th. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating and seven have given a buy rating to the company’s stock. Perrigo currently has an average rating of “Hold” and a consensus target price of $85.31.
Perrigo Company Profile
Perrigo Company plc is a global healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, animal health, dietary supplements, active pharmaceutical ingredients (API), and medical diagnostic products, and Multiple Sclerosis drug Tysabri.
Want to see what other hedge funds are holding PRGO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Perrigo Company (NYSE:PRGO).
Receive News & Ratings for Perrigo Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perrigo Company and related companies with MarketBeat.com's FREE daily email newsletter.